文献速递乳腺癌支持与姑息治疗

乳腺癌患者中意义未明克隆性造血的发生率、动态变化及预后作用

Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
PubMed 文献 · J Clin Oncol · 2024-01-08

该研究对380例乳腺癌患者的614份样本进行靶向纠错测序,前瞻性分析早期乳腺癌患者接受化疗或内分泌治疗后意义未明克隆性造血(CHIP)的动态变化,并评估其与转移性三阴性乳腺癌生存的相关性及向治疗相关髓系肿瘤进展的风险。结果显示治疗前CHIP发生率为15%,化疗未导致新发CHIP,但增加变异等位基因频率(VAF)≥0.005的新发克隆性造血风险(OR 3.45,P=0.002),且出现5例TP53突变克隆。

要点

  • 乳腺癌患者治疗前CHIP发生率为15%。
  • 化疗较内分泌治疗未增加新发CHIP风险(OR 1.16,P=0.820)。
  • 化疗增加VAF≥0.005的新发克隆性造血风险(OR 3.45,P=0.002),出现5例TP53突变克隆。

核心结论

  • CHIP在乳腺癌患者中常见,本研究中化疗未导致新发CHIP,多数患者治疗相关髓系肿瘤风险低。
  • 但化疗后出现VAF≥0.005的TP53突变克隆性造血,此类克隆与治疗相关髓系肿瘤高风险相关,其演变及临床意义需进一步研究。

研究设计与样本

  • 对380例乳腺癌患者的614份样本进行靶向纠错测序。
  • 前瞻性收集早期乳腺癌患者接受化疗或内分泌治疗的配对样本,分析CHIP动态变化。
  • 评估CHIP与转移性三阴性乳腺癌生存的相关性,并根据克隆性造血风险评分(CHRS)估计向治疗相关髓系肿瘤进展的风险。
  • 探索性分析中考虑VAF≥0.005的克隆性造血。

主要发现

  • 治疗前15%的患者检测到CHIP。
  • 治疗后新发CHIP较少,化疗与内分泌治疗患者发生新突变的风险相似(OR 1.16,P=0.820)。
  • 化疗增加VAF≥0.005的新发克隆性造血风险(OR 3.45,P=0.002)。
  • 接受化疗的患者中出现5例VAF≥0.005的TP53突变克隆性造血。
  • 根据CHRS评分,多数患者治疗相关髓系肿瘤风险低;CHIP与转移性三阴性乳腺癌生存无相关性。

局限性

  • 这些小型克隆的演变及其临床意义需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clonal hematopoiesis of indeterminate potential (CHIP) is frequent in patients with solid tumors. Prospective data about CHIP prevalence at breast cancer diagnosis and its dynamic evolution under treatment selective pressure are limited. PATIENTS AND METHODS: We performed targeted error-corrected sequencing on 614 samples from 380 patients with breast cancer. We investigated the dynamics of CHIP on prospectively collected paired samples from patients with early breast cancer (eBC) receiving chemotherapy (CT) or endocrine therapy (ET). We assessed the correlation of CHIP with survival in patients with metastatic triple-negative breast cancer (mTNBC). We estimated the risk of progression to treatment-related myeloid neoplasms (t-MN) according to the clonal hematopoiesis risk score (CHRS). In exploratory analyses, we considered clonal hematopoiesis (CH) with variant allele fraction (VAF) ≥0.005. RESULTS: CHIP was identified in 15% of patients before treatment. Few CHIP emerged after treatment, and the risk of developing new mutations was similar for patients receiving CT versus ET (odds ratio [OR], 1.16; P = .820). However, CT increased the risk of developing new CH with VAF ≥0.005 (OR, 3.45; P = .002). Five TP53-mutant CH with VAF ≥0.005 emerged among patients receiving CT. Most patients had low risk of t-MN according to the CHRS score. CHIP did not correlate with survival in mTNBC. CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF ≥0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Morganti S, Gibson CJ, Jin Q, et al. Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. J Clin Oncol. 2024. PMID: 38190580. doi:10.1200/JCO.23.01071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。